Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids




Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids

Trial #MDTCT2026 Now Enrolling 50 Participants Diagnosed with Unilateral Meniere’s Disease

Grand Rapids, Michigan, U.S.A., Feb. 19, 2026 (GLOBE NEWSWIRE) —

Burcon Chiropractic Announces Clinical Trial for Meniere’s Disease Treatment

Burcon Chiropractic, in collaboration with the Meniere’s Research Institute, has announced the launch of a clinical trial (Trial #MDTCT2026) focused on patients diagnosed with unilateral Meniere’s disease. The study is being conducted in Grand Rapids, Michigan and will enroll up to 50 qualified participants beginning February 1, 2026.

The purpose of this clinical trial is to further investigate upper cervical care approaches in patients experiencing vertigo, hearing changes, and related symptoms associated with Meniere’s disease.

Enrollment will remain open until all 50 positions are filled.

Location

Grand Rapids, Michigan, U.S.A.

Eligibility Criteria

Participants must provide:

• Documentation confirming diagnosis of unilateral Meniere’s disease by an otolaryngologist
• Upright MRI of the head and neck, including the CranioCervical Junction (CCJ)
• Hearing test results demonstrating low-frequency hearing loss in the affected ear
• History of at least two unexplained vertigo attacks with nausea
• Completed new patient paperwork (available at www.BurconChiropractic.com)
• Completed universal Meniere’s disease questionnaire
• Availability for three office visits over a minimum of two days to two weeks in Grand Rapids, MI

Potential Benefits

Participants may:

• Contribute to ongoing Meniere’s disease research
• Experience reduction in frequency and intensity of vertigo episodes
• Receive up to $2,500 in treatment cost savings

WATCH HEALTH TALK VIDEOS

Illustrations:

1. 90% improvement with vertigo in 300 consecutive MD patients

   

2. Strong correlation between trauma and onset of Meniere’s at average of 15 years

About the Research

According to Dr. Burcon of Burcon Chiropractic, the clinical trial builds upon years of observational data examining possible correlations between prior head or neck trauma and the later onset of Meniere’s symptoms.

The study focuses on evaluating structural and neurological factors at the cranio-cervical junction using upright MRI imaging and upper cervical analysis.

Dr. Burcon has presented research related to Meniere’s disease at multiple international forums over the past 25 years, including conferences hosted by the Barany Society, House Ear Institute, Politzer Society, and International Meniere’s Disease Symposiums.

Contact Information

Meniere’s Research Institute
Burcon Chiropractic
3501 Lake Eastbrook Blvd SE
Suite 252
Grand Rapids, MI 49546

Phone: 616-575-9990
Text: 616-647-7946
Email: DrBurcon@yahoo.com

Additional Treatment Information

Individuals who do not meet all clinical trial requirements may still pursue treatment. The first three visits are available for $2,500. An intensive 12-visit care package is available for $5,000. Future visits are $150.

CONTACT: Name: Michael Burcon
Company: Meniere's Research Institute, a division of Burcon Chiropractic
Email: DrBurcon@yahoo.com
Website: https://BurconChiropractic.com
Phone: 1 616-575-9990

Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care




Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care

RICHMOND, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) — Family Insight, PC, a Whitecap Care, LLC company and a leader in value-based care (VBC) and behavioral health, announces the appointment of Kyle Williamson as vice president of Business Development, strengthening the organization’s commitment to scalable partnerships with payers, healthcare systems, physician practices and high-performing value-based care models. In his new role, Williamson will lead business development strategy and support the program as it expands to multi-state partnerships and continued innovation in value-based care delivery.

“Williamson’s past partnership with Family Insight and his leadership role in developing, building and scaling Optum’s Integrated Behavioral Health Home (IBHH) program adds to our successful business model,” says Tim Kyle, CEO. “This is not simply a hire, it’s the continuation of a highly respected executive with a proven partnership that strengthens our ability to expand and deliver results for payers, providers, and the communities we serve. His transition into this leadership role formalizes a partnership that has already delivered measurable impact.”

At Optum, Williamson held a crucial management position and gained direct experience in architecting an initiative focused on the coordination of medical, behavioral, and social care for individuals with complex needs. Importantly, he was key in establishing Family Insight, PC as a vital partner for supporting this program within Virginia.

Following his tenure at Optum, Williamson evaluated numerous opportunities across the healthcare landscape but ultimately chose Family Insight because of its reputation, provider-focused culture, clear vision for the future of value-based care and focus on the overall health of the members.

“Of all of the VBC programs that I worked with, Family Insight stands out because of how intentionally they build and execute their programs,” says Williamson. “Their focus on outcomes, accountability, and true payer-provider alignment reflects exactly where healthcare needs to go. I’m excited to help grow what we’ve created together.”

Williamson brings expertise in healthcare strategy, payer-provider collaboration and value-based program development to Family Insight’s VBC team, extending Family Insight’s Complete Care Stewardship™ program with health plans, managed care organizations, accountable care organizations and hospitals across multiple states. Over the past three years, Family Insight worked closely with Williamson to refine and optimize its care delivery model based upon Optum’s requirements as well as his expectations. This collaboration helped shape the program design, operational standards and payer alignment strategies that now serve as the foundation for the company’s value-based platform.

About Family Insight, PC
Headquartered in Richmond, Virginia, Family Insight, PC specializes in Value-Based Care, integrating both medical and behavioral health to treat the whole person. We are dedicated to supporting children, adolescents, adults, and families through a comprehensive range of mental health and wellness services designed to improve long-term outcomes. https://familyinsight.net/

Media:

Laura Carabello
CPR Strategic Marketing Communications
lcarabello@cpronline.com
551.259.8248

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026




Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

• CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections
• Company to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of Medicine
• No approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need

BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39^th International Conference on Antiviral Research (ICAR2026), being held April 27–May 1 in Prague, Czech Republic. CDI-988 is the first oral antiviral drug candidate under development for the prevention and treatment of acute norovirus gastroenteritis.

Sam Lee, Ph.D., Cocrystal President and co-CEO, will discuss the ongoing Phase 1b challenge study evaluating CDI-988 as both a potential prophylactic and therapeutic option for norovirus infection. CDI-988 was designed and developed using the Company’s proprietary structure-based drug discovery platform technology as a pan-viral protease inhibitor, targeting 3CL viral proteases. Based on its novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a potential oral treatment for both noroviruses and coronaviruses.

“ICAR is widely regarded as the premier international conference for antiviral research, and it is a privilege to be selected to present our work to this antiviral research community,” said Dr. Lee. “We are excited to further advance CDI-988 into a Phase 1b norovirus challenge study at Emory University School of Medicine. CDI‑988 is our first pan-viral protease inhibitor developed for the treatment of acute norovirus gastroenteritis and also represents a significant step toward a potential treatment for patients suffering from chronic norovirus infection.”

About ICAR2026

The International Society for Antiviral Research (ISAR) is an internationally recognized organization of scientists working across the basic, applied, translational and clinical aspects of antiviral research. The annual International Conference on Antiviral Research (ICAR), the Society’s main event, brings together virologists, chemists, clinicians, pharmacologists, biologists and regulatory representatives focused on antiviral agents and therapies. Topics include novel and broad‑spectrum antivirals, host‑targeted approaches, vaccines, pandemic preparedness and emerging or re‑emerging viral threats, with a strong emphasis on interdisciplinary collaboration among academia, industry, government and non‑profit organizations.

About Norovirus

Norovirus is a common and highly contagious virus that afflicts people of all ages and causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea, as well as fatigue, fever and dehydration. This infection spreads rapidly in semi-closed and crowded settings such as hospitals, nursing homes, cruise ships, schools, disaster-relief shelters and military facilities, where close contact makes outbreaks especially difficult to control. Norovirus causes an estimated 200,000 deaths worldwide each year at a societal cost of approximately $60 billion. In the U.S., norovirus is responsible for about 21 million cases of acute gastroenteritis annually, including 109,000 hospitalizations, 465,000 emergency department visits and nearly 900 deaths, with an estimated annual economic burden of $10.6 billion.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of CDI-988 as an oral treatment for both norovirus and coronavirus infections. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from inflation, affordability, the possibility of a recession, the impact of future interest rate changes on the economy, tariffs and the resulting litigation, and geopolitical conflicts including those in Ukraine, Latin America and Middle East on our Company, our collaboration partners, and on the U.S. and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with the planned norovirus study or subsequent studies as well as similar problems with our vendors and our current and any future clinical research organizations (CROs) and contract manufacturing organizations (CMOs), the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the potential for the development of effective treatments by competitors which could reduce or eliminate a prospective future market share commercializing any product candidates we may develop in the future, and our ability to meet our future liquidity needs. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 and the Prospectus dated September 25, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:

Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

# # #

Philips publishes its Annual Report 2025




Philips publishes its Annual Report 2025

February 19, 2026

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025.

Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.

Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).

The Annual Report 2025 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 614 869 261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors




Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors

Pharma, Biotech and Medtech Sector Leader and Entrepreneur to Drive Further Growth and Strategic Expansion

DEESIDE, United Kingdom, Feb. 19, 2026 (GLOBE NEWSWIRE) — Reacta Healthcare Ltd, a leading developer of food allergy diagnostic products, today announces the appointment of Richard Nagle as Chair of its Board of Directors.

Richard brings more than 30 years’ experience in the pharmaceutical, biotechnology and medical technology sectors including in immunology. He has founded and led multiple companies, raised tens of millions of dollars of funding, achieved a number of successful exits and delivered operational transformations as companies grow.

Among his senior leadership positions, Richard was a Strategic Advisor and CEO at Immune Regulation (now Revolo Biotherapeutics and formerly Peptinnovate) in which roles he oversaw significant strategic advancements, clinical and product development programs and corporate development during periods of significant growth. In addition to his role as Chair of Reacta Healthcare, he is a part-time Executive Director at SASPiPhi, a company developing precision antimicrobials.

Richard’s appointment strengthens Reacta’s senior leadership as the Company continues its rapid growth driven by its leading position as the only oral food challenge product manufactured under full pharmaceutical GMP, and its innovation pipeline which will fuel future strategic expansion.

Professor Ashley Woodcock, a co-founder of Reacta Healthcare and Chair since inception, remains with the Company in a Non-Executive Director role.

Dr. Paul Abrahams, Reacta Healthcare CEO, said: “We are thrilled to have Richard join us at such a pivotal time in the Company’s growth trajectory. His specific knowledge in the immunology space and broad experience in finance, corporate strategy and product development adds huge value and strengthens our strategic leadership. The senior team and I are looking forward to working with Richard to refine and deliver on an ambitious strategy for 2026 and beyond.

“We are hugely grateful to Ashley for his entrepreneurial leadership, guidance and support of Reacta to date and look forward to his ongoing contribution to the business as a Non-Executive Director.”

Richard Nagle, Reacta Healthcare Chair, added: “This is an extremely exciting time for Reacta, and I am delighted to be joining this dynamic business. Reacta has been at the forefront of food allergy diagnostics R&D and counts many of the leading companies in the allergy therapeutic development space as its partners. Our aim now is to continue to expand our presence both in the UK and internationally, delivering solutions that improve the safety, accuracy and efficiency of food allergy testing.

“Reacta has built a world class team to execute on its future development goals, and I look forward to working with Paul and the management team in helping them to realise maximum value from its pioneering products and deep innovation pipeline.”

Reacta was recently placed 12^th in The Sunday Times Tech100 2026 fastest-growing private tech companies having expanded its multi-allergen product range to include milk and egg as well as peanut challenge meals.

About Reacta Healthcare

Reacta Healthcare is an innovative company setting a new standard in oral food challenge (OFC) products to empower the development of therapies and diagnostics to transform the lives of the millions of people living with food allergy worldwide.

The Company manufactures its products in a dedicated pharmaceutical GMP licensed-facility in the UK. The only OFC supplier working to this standard and operating worldwide.

Reacta Healthcare has been supplying clinical trials since 2017 and its OFC products have been used at over 300 sites in Europe, North America, Australia and New Zealand.

A fast-growing, profitable private company, Reacta Healthcare works with biotechnology companies, CROs and pharmaceutical majors globally and is drawing on its heritage and proven track record in food and pharmaceutical science to develop a rich pipeline of future products and solutions for the allergy market. Patents for its challenge meals have been granted in a number of countries.

For further information, please contact:

Media

Charles Consultants

Sue Charles, E: sue.charles@charles-consultants.com M: +44 (0)7968 726585
Chris Gardner, E: Chris@CGComms.onmicrosoft.com M: +44 (0)7956 031077

At the Company

Lara Marks
Marketing & Communications Officer
E: lara.marks@reactahealthcare.com T: +44 (0)3332 423 042

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants




Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the “Offering”) of 6,428,574 common shares of the Company (the “Common Shares”) at a price to the public of US$7.00 per Common Share and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.00001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$55 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. Each pre-funded warrant will entitle the holder thereof to acquire one common share of the Company (a “Pre-Funded Warrant Share”) at a nominal exercise price of C$0.00001 per Pre-Funded Warrant Share and will not expire until exercised in full. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,178,571 Common Shares on the same terms and conditions. All of the Common Shares and Pre-Funded Warrants in the Offering are being sold by the Company. The Offering is expected to close on February 20, 2026, subject to the satisfaction of customary closing conditions, including the listing of the Common Shares and Pre-Funded Warrant Shares to be issued under the Offering on the Toronto Stock Exchange (the “TSX”) and the Nasdaq Capital Market (the “Nasdaq”), and receipt of any required approvals of the TSX.

Cantor and LifeSci Capital are acting as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum are also acting as co-managers for the Offering.

The Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

The Offering is being made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the “SEC”) on February 7, 2024, and the Company’s existing Canadian short form base shelf prospectus, (the “Base Prospectus”) dated February 5, 2024. A preliminary prospectus supplement relating to and describing the terms of the Offering has been filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to and describing the terms of the Offering (the “Supplement”) will be filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40^th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com, from Bloom Burton Securities Inc. at ecm@bloomburton.com, or from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Suite 300, Minneapolis, MN 55401, or by telephone at (612) 334-6300, or by email at prospectus@chlm.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Offering, whether and when the Offering may close, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds from the Offering; and the potential for the Company’s technology to impact the drug delivery process. Such statements and information are based on the current expectations of Eupraxia’s management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company’s ability to obtain positive results from the Company’s research and development activities, including clinical trials; and the Company’s ability to protect patents and proprietary rights. Although Eupraxia’s management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company’s limited operating history; the Company’s novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company’s current license agreement may not provide an adequate remedy for its breach by the licensor; the Company’s technology may not be successful for its intended use; the Company’s future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company’s clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company’s ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company’s operations; the Company’s restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company’s common share price; and other risks and uncertainties described in more detail in Eupraxia’s public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

Rapid Nutrition PLC – Strategic Outlook and Near-Term Execution Update




Rapid Nutrition PLC – Strategic Outlook and Near-Term Execution Update

Well-capitalised HealthTech group enters delivery phase across platform expansion, selective acquisitions and science-led product development

LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) — Rapid Nutrition PLC, a HealthTech company trading on Euronext Growth Paris (ALRPD), provides a strategic outlook update as the Company enters a focused execution phase across its core growth initiatives.

Rapid Nutrition is transitioning from a premium nutraceuticals business to a personalised, platform-led HealthTech operating model focused on evidence-based nutrition and immune wellness. Supported by an established operating portfolio, subscription-led engagement and disciplined capital allocation, the Company is further anchored by recent long-term institutional funding and is well-capitalised to execute.

The Board believes the Company has reached an inflection point, moving from strategy to delivery.

The Company operates a portfolio of science-led wellness brands that generate revenue today and underpin its platform strategy. SystemLS® delivers evidence-based nutrition products supported by personalised assessment frameworks. Azurene™ focuses on immune and preventive wellness through differentiated formulations, including blends originally developed as patented combinations of herbs, with ongoing refinement and expansion across APAC.

In addition, Rapid Nutrition is selectively expanding its product portfolio through licensed, evidence-based ingredients in high-demand functional nutrition categories.

Rapid Nutrition operates a diversified, multi-channel business model across direct-to-consumer, subscription, wholesale, practitioner and strategic partnership channels. As part of its platform-led growth strategy, the Company has entered discussions with a target group aligned with its strategic criteria and is confident in its ability to progress the opportunity in the near term, subject to customary diligence and approvals.

Near-Term Execution Priorities

• Expansion of personalised assessment frameworks
• Acceleration of product-led growth in priority evidence-based categories
• Optimisation of direct-to-consumer and marketplace channels
• Targeted international expansion across APAC and the United States
• Progression of selective expansion and consolidation initiatives

The Board remains confident in the Company’s growth trajectory and expects the upcoming financial period to reflect meaningful progress across its strategic priorities.

About Rapid Nutrition

Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.

Investor Relations Contact:
ir@rnplc.com

Media Contact:
Fairfaxpartners: Fair@ir.fairfax.partners

Disclaimer
This announcement contains forward-looking statements, including statements regarding the Company’s expectations, intentions, plans, beliefs or forecasts. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or developments to differ materially from those expressed or implied by such statements. These forward-looking statements are based on assumptions and assessments made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements speak only as at the date of this announcement.

Except as required by applicable law or regulation, Rapid Nutrition PLC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are provided for illustrative purposes only and are not guarantees of future performance.

This announcement is for information purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of Rapid Nutrition PLC in any jurisdiction. This announcement does not constitute a prospectus, offering memorandum or admission document for the purposes of the UK prospectus regime, Regulation (EU) 2017/1129 (the “Prospectus Regulation”), the U.S. Securities Act of 1933 (as amended), or the rules of any securities exchange or trading venue.

The distribution of this announcement may be restricted by law in certain jurisdictions. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Rapid Nutrition PLC has engaged Fairfax Partners Inc., based in Vancouver, British Columbia, to provide investor relations and communications services. The service agreement has an initial term of three months commencing January 1, 2026. In consideration for the services, the Company will pay Fairfax Partners a monthly cash fee of €50,000 plus applicable taxes. Fairfax Partners is an independent third-party service provider. Neither Fairfax Partners nor its principals

ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine




ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who Experience Challenges Taking Daily Oral Treatment

CHAPEL HILL, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of “Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges” in the New England Journal of Medicine (NEJM). The publication reports that the long-acting injectable cabotegravir and rilpivirine was superior in preventing regimen failure among people living with HIV who have struggled with adherence to daily oral antiretroviral therapy (ART).

This publication reports on the LATITUDE study, also known as A5359, a phase 3 efficacy study of long-acting cabotegravir and rilpivirine, which is approved in the U.S. to be used as an injection every one or two months for people living with HIV with a consistent history of viral suppression. Because only an estimated 67% of people living with HIV in the U.S. who take oral ART maintain viral suppression, LATITUDE sought to determine whether this long-acting approach could achieve consistent virologic suppression among people who have difficulty taking oral ART. It is the first randomized study to do so.

“LATITUDE is a groundbreaking study, and these results enable us to significantly expand the population of individuals who will benefit from this long-acting treatment option,” said ACTG Chair Joseph J. Eron, M.D., University of North Carolina. “Since the U.S. Food and Drug Administration approved cabotegravir and rilpivirine in 2021, observational cohorts and case studies have suggested that these injectable agents may support viral suppression among people living with HIV who struggle with daily oral pills. Today’s publication validates the approach and will make a substantial difference in the experiences of these individuals living with HIV.”

LATITUDE enrolled 453 participants who demonstrated challenges taking daily oral ART or had disengaged from HIV care. The median age was 40 years; 63 percent were Black, 29 percent were female, 17 percent were Hispanic, and 14 percent reported either ongoing or prior injection drug use. Once enrolled, participants received adherence support including economic incentives to achieve viral suppression while taking daily oral ART. Researchers randomized 306 participants who were able to achieve viral suppression to either receive long-acting injectable ART every four weeks or continue taking standard-of-care daily oral ART. In February 2024, an independent Data and Safety Monitoring Board (DSMB) recommended halting randomization and inviting all eligible study participants to take long-acting ART based on interim efficacy data.

Today’s publication demonstrates that the risk of regimen failure (a measure that includes individuals experiencing unsuppressed HIV or discontinuing ART for any reason) through 48 weeks of treatment was almost twice as high in those continuing on oral ART compared to those who were switched to long-acting treatment (41.2 percent vs. 22.8 percent). Among the 152 participants receiving long-acting ART, 29 experienced regimen failure, five of whom had virologic failure and 24 had permanent treatment discontinuation as their first event. That compares to 55 of the 154 participants receiving daily ART who experienced regimen failure, among whom 32 had virologic failure as their first event and 23 had permanent treatment discontinuation.

Side effects were similar between study arms. The most common side effect in the long-acting arm was injection-site reactions (60 percent) with only two participants discontinuing as a result. There were four participants total (two in each arm) who acquired HIV resistance-associated mutations.

“The initial studies upon which the approval of long-acting cabotegravir and rilpivirine were based generally excluded people living with HIV who had viremia and who were not able to adhere to daily oral ART,” said study Chair Aadia Rana, M.D., University of Alabama at Birmingham. “People struggle to take daily HIV treatment for a variety of reasons, including social and structural barriers, side-effects, stigma, and competing priorities. It is vital we ensure that all individuals have access to the same robust set of HIV treatment options and the findings from LATITUDE are an important milestone toward that goal. The most important next steps will include ways to effectively implement these agents among these communities.”

LATITUDE is led by Dr. Rana and Raphael J. Landovitz, M.D., M.Sc., University of California Los Angeles and Karen Tashima, M.D., Brown University (Vice Chairs). ACTG is led by Dr. Eron and Rajesh T. Gandhi, M.D., Massachusetts General Hospital and Harvard Medical School (ACTG Vice Chair). It is sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634, and received additional funding from UTHealth Houston McGovern School of Medicine. ViiV Healthcare and Johnson & Johnson provided medications for the study.

About ACTG
ACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at 65 locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve.

Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH.

Media Contact:
Jenna Conley, ACTG
jenna@conleycommunications.net

ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine




ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who Experience Challenges Taking Daily Oral Treatment

CHAPEL HILL, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of “Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges” in the New England Journal of Medicine (NEJM). The publication reports that the long-acting injectable cabotegravir and rilpivirine was superior in preventing regimen failure among people living with HIV who have struggled with adherence to daily oral antiretroviral therapy (ART).

This publication reports on the LATITUDE study, also known as A5359, a phase 3 efficacy study of long-acting cabotegravir and rilpivirine, which is approved in the U.S. to be used as an injection every one or two months for people living with HIV with a consistent history of viral suppression. Because only an estimated 67% of people living with HIV in the U.S. who take oral ART maintain viral suppression, LATITUDE sought to determine whether this long-acting approach could achieve consistent virologic suppression among people who have difficulty taking oral ART. It is the first randomized study to do so.

“LATITUDE is a groundbreaking study, and these results enable us to significantly expand the population of individuals who will benefit from this long-acting treatment option,” said ACTG Chair Joseph J. Eron, M.D., University of North Carolina. “Since the U.S. Food and Drug Administration approved cabotegravir and rilpivirine in 2021, observational cohorts and case studies have suggested that these injectable agents may support viral suppression among people living with HIV who struggle with daily oral pills. Today’s publication validates the approach and will make a substantial difference in the experiences of these individuals living with HIV.”

LATITUDE enrolled 453 participants who demonstrated challenges taking daily oral ART or had disengaged from HIV care. The median age was 40 years; 63 percent were Black, 29 percent were female, 17 percent were Hispanic, and 14 percent reported either ongoing or prior injection drug use. Once enrolled, participants received adherence support including economic incentives to achieve viral suppression while taking daily oral ART. Researchers randomized 306 participants who were able to achieve viral suppression to either receive long-acting injectable ART every four weeks or continue taking standard-of-care daily oral ART. In February 2024, an independent Data and Safety Monitoring Board (DSMB) recommended halting randomization and inviting all eligible study participants to take long-acting ART based on interim efficacy data.

Today’s publication demonstrates that the risk of regimen failure (a measure that includes individuals experiencing unsuppressed HIV or discontinuing ART for any reason) through 48 weeks of treatment was almost twice as high in those continuing on oral ART compared to those who were switched to long-acting treatment (41.2 percent vs. 22.8 percent). Among the 152 participants receiving long-acting ART, 29 experienced regimen failure, five of whom had virologic failure and 24 had permanent treatment discontinuation as their first event. That compares to 55 of the 154 participants receiving daily ART who experienced regimen failure, among whom 32 had virologic failure as their first event and 23 had permanent treatment discontinuation.

Side effects were similar between study arms. The most common side effect in the long-acting arm was injection-site reactions (60 percent) with only two participants discontinuing as a result. There were four participants total (two in each arm) who acquired HIV resistance-associated mutations.

“The initial studies upon which the approval of long-acting cabotegravir and rilpivirine were based generally excluded people living with HIV who had viremia and who were not able to adhere to daily oral ART,” said study Chair Aadia Rana, M.D., University of Alabama at Birmingham. “People struggle to take daily HIV treatment for a variety of reasons, including social and structural barriers, side-effects, stigma, and competing priorities. It is vital we ensure that all individuals have access to the same robust set of HIV treatment options and the findings from LATITUDE are an important milestone toward that goal. The most important next steps will include ways to effectively implement these agents among these communities.”

LATITUDE is led by Dr. Rana and Raphael J. Landovitz, M.D., M.Sc., University of California Los Angeles and Karen Tashima, M.D., Brown University (Vice Chairs). ACTG is led by Dr. Eron and Rajesh T. Gandhi, M.D., Massachusetts General Hospital and Harvard Medical School (ACTG Vice Chair). It is sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634, and received additional funding from UTHealth Houston McGovern School of Medicine. ViiV Healthcare and Johnson & Johnson provided medications for the study.

About ACTG
ACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at 65 locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve.

Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH.

Media Contact:
Jenna Conley, ACTG
jenna@conleycommunications.net